Report library

Zytiga

Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis.

January 18, 2018

MDS/AML KOL Interview

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

April 9, 2015

Company Analysis: Pfizer

$3,000.00

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

August 28, 2020

Heart Valve Repair and Replacement Devices Market

The global market for heart valve repair and replacement devices is being driven by the increasing burden of heart valve disease, which left untreated can lead to severe and life-threatening cardiovascular diseases. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the worldwide heart valve repair and replacement devices market, which includes percutaneous balloon valvuloplasty, heart valve surgery, transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve regurgitation therapy (TMVrep). Global heart valve repair and replacement device sales are projected to expand at a compound annual growth rate (CAGR) of 10.9% during 2016-21, increasing from approximately $4,834.7m in 2016 to an estimated $8,094.4m in 2021. Countries/regions covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of the World segment (which combines estimated sales data for all other countries).

July 1, 2017

Cayston

Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead.

September 3, 2018

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

May 20, 2019

ADPD Alzheimer’s Disease Pulse

Overview We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification. Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).

March 19, 2015

Suglat

Suglat (ipragliflozin; Astellas/Kotobuki Pharmaceutical/Merck & Co) is a competitive inhibitor of sodium-glucose cotransporter-2 (SGLT-2), approved for the treatment of type 2 diabetes. Inhibition of SGLT-2 prevents reabsorption of glucose in the proximal tubule of the kidney, thus resulting in glucose excretion in the urine.

U.S. Markets for Anesthesia and Ventilation Products, February 2015

A major driver of the U.S. anesthesia delivery systems market is the increase in surgical procedure volumes; this is largely due to the aging of the population, and will continue over the forecast period covered by this report.

February 1, 2015

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.

February 6, 2019

Disease Analysis: Type 2 Diabetes

Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.

October 20, 2021

SaxaDapa

SaxaDapa is a fixed-dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT-2) inhibitor Farxiga (dapagliflozin; AstraZeneca) and dipeptidyl peptidase-IV inhibitor Onglyza (dapagliflozin; AstraZeneca/Kyowa Hakko Kirin).

Datamonitor Malignant Melanoma Pricing and Reimbursement

Malignant Melanoma Pricing, Reimbursement and Access

$2,995.00

This strategy report focuses on Malignant Melanoma Pricing and Reimbursement including how immunotherapies are changing melanoma treatment paradigms with market conext in the US, Japan, and five major EU markets.

September 30, 2015

Accountable Care Organizations – What Impact on Pharma

$7,500.00

This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.

July 16, 2015

Azilect

Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.

June 21, 2018

Januvia

Januvia (sitagliptin; Merck & Co) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

Venclexta

Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.

January 31, 2019

Vibativ

Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.

September 10, 2014

Tenelia

Tenelia (teneligliptin; Mitsubishi Tanabe) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut.

Surgical Heart Valve Management Products

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the surgical heart valve repair (annuloplasty) systems, surgical heart valve replacement products, and percutaneous balloon valvuloplasty (PBV) systems markets.

May 16, 2019

Uptravi

Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.

October 29, 2018

Cochlear Implants Market

This report includes: an overview of hearing loss, cochlear implant technology, competition, trends, and market analysis. Market analysis includes 5-year market forecast by region, market drivers/limiters, global market share and market share by region.

February 28, 2019

Market Spotlight: Axial Spondyloarthritis (axSpA)

$1,318.00

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

September 23, 2021

ralinepag

Ralinepag (Arena Pharmaceuticals/Everest Medicines) is a selective prostaglandin I2 receptor agonist. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, which also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.

October 29, 2018

Orenitram

United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.

October 19, 2018

Breast Cancer Pulse #2

We performed a 5-question survey of 24 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs and drug candidates discussed: •Neratinib, PBYI •Herceptin (trastuzumab), Roche •Perjeta (pertuzumab), Roche •Kadcyla (trastuzumab-DM1), Roche •Tykerb (lapatinib), GSK

October 31, 2016

Post-AAIC KOL Interview

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

August 6, 2014

Sovaldi

Sovaldi (sofosbuvir; Gilead) was the first interferon-free regimen to be approved for genotype 2/3 (GT-

2/3) patients, and has greatly benefited from the lucrative warehoused population and lack of

competitors in this subgroup.

November 6, 2017

Psoriasis Pricing, Reimbursement, and Access

$2,995.00

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

March 28, 2019